Indivior
Focus: Indivior is a UK-based biotech specializing in addiction treatment, predominantly focused on opioid-use disorder therapeutics. The company is heavily concentrated on the SUBOXONE franchise, which generates 72% of revenue.
Profile data last refreshed 2h ago · AI intelligence enriched 1w ago
Open Jobs
0
About Indivior
AI assessmentNot HiringNo open roles listed right now. Follow Indivior to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Indivior's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Late-stage
8 Phase 3+
LOE Risk
1 imminent
PERSERIS KIT
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$95M Part DDeclining
Peak
Help build intelligence for Indivior
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.